๐ŸงFreshcollected in 3m

NewDays Takes AI Dementia Care to Nevada

NewDays Takes AI Dementia Care to Nevada
PostLinkedIn
๐ŸงRead original on GeekWire
#dementia-care#telehealth#healthcare-ai#seed-fundingnewdaysnewdayssunny

๐Ÿ’กSee how NewDays combines an AI companion, telehealth clinicians, and clinical outcomes to scale dementia care.

โšก 30-Second TL;DR

What Changed

NewDays expanded its seed round to $16 million.

Why It Matters

The expansion signals growing demand for AI-enabled care models that combine automated engagement with human clinical oversight. For AI healthcare builders, NewDays highlights the importance of pairing conversational systems with regulated clinical workflows and outcome measurement.

What To Do Next

Review Sunny's clinician-escalation workflow and require outcome metrics before adopting a similar AI companion in a care product.

Who should care:Founders & Product Leaders

Key Points

  • โ€ขNewDays expanded its seed round to $16 million.
  • โ€ขIts platform combines telehealth clinicians with the AI companion Sunny.
  • โ€ขThe service is expanding to Nevada and six states overall.
  • โ€ขEarly research indicates potential cognitive-function preservation of up to 18 months.

๐Ÿง  Deep Insight

Background and context from public sources โ€” not the original article. 7 sources cited.

๐Ÿ”‘ Enhanced Key Takeaways

  • โ€ขNewDays was co-founded by Babak Parviz, the former Google Glass project lead and Amazon VP, alongside former Google X engineering leader Daniel Kelly.
  • โ€ขThe company's intervention methodology is explicitly grounded in the Internet-Based Conversational Engagement Clinical Trial (I-CONECT) research framework.
  • โ€ขThe platform's efficacy was validated in a pilot study of over 1,000 users, which yielded a 4.5/5 satisfaction rating and 100% self-reported improvement in well-being.
  • โ€ขThe service model is positioned as a non-drug, scalable alternative to traditional, resource-intensive clinical care for Alzheimer's and mild cognitive impairment (MCI).
  • โ€ขPrior to the current $16 million expansion, the company secured $7 million in funding in September 2025 to initiate its multi-state growth strategy.

๐Ÿ› ๏ธ Technical Deep Dive

  • The platform utilizes a hybrid architecture that integrates AI-driven daily cognitive exercises with synchronous telehealth sessions led by licensed clinicians.
  • The AI companion Sunny is designed for personalized, daily conversational engagement to specifically target memory, mood, focus, and attention metrics.
  • The system leverages conversational AI to facilitate longitudinal cognitive monitoring, mirroring the engagement protocols established in the I-CONECT clinical trials.

๐Ÿ”ฎ Future ImplicationsAI analysis grounded in cited sources

NewDays will seek FDA clearance for its cognitive intervention platform.
The company's reliance on clinical trial frameworks like I-CONECT suggests a strategy to transition from a wellness service to a regulated digital therapeutic.
The company will integrate biometric data from wearable devices into the Sunny AI companion.
Given the founders' background in hardware (Google Glass) and the need for objective cognitive decline tracking, integrating passive health data is a logical technical progression.

โณ Timeline

2025-09
NewDays secures $7 million in funding to initiate expansion of its cognitive treatment services.
2026-09
NewDays announces expansion to Nevada and total funding increase to $16 million.

๐Ÿ“Ž Sources (7)

Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.

  1. indeed.com
  2. aginglifecare.org
  3. newdays.ai
  4. fiercehealthcare.com
  5. newdays.ai
  6. newdays.ai
  7. transistor.fm
๐Ÿ“ฐ

Weekly AI Recap

Read this week's curated digest of top AI events โ†’

๐Ÿ‘‰Related Updates

AI-curated news aggregator. All content rights belong to original publishers.
Original source: GeekWire โ†—

This is a summary, not the original. Read the source, or get the weekly briefing.

Weekly AI briefing

One email a week. Unsubscribe anytime.